Concert Pharmaceuticals (United States)

Recent papers from Concert Pharmaceuticals (United States)

1. Validation of an all-source composite mortality endpoint in the US populationJournal of Comparative Effectiveness Research · 2026
2. Collaborative care treatment for major depressive disorderFrontiers in Psychiatry · 2026
3. Association between the different basic activities of daily living on the Barthel index and community living, use of mobility aids, and the survival at 5 yearsFrontiers in Public Health · 2026
4. Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE InitiativeClinical Pharmacology & Therapeutics · 2026
5. Clinical outcomes among patients with metastatic non–small cell lung cancer (mNSCLC) who received immune checkpoint inhibitors (ICI) in first (1L) and second line (2L).Journal of Clinical Oncology · 2026
6. National perspectives on artificial intelligence use in cancer care: Confidence, adoption, and barriers.Journal of Clinical Oncology · 2026
7. Developing a pan-cancer foundation model for digital patient representation and clinical prediction across real-world oncology data.Journal of Clinical Oncology · 2026
8. A multi-agent AI system integrating real-world data and competitive intelligence to generate automated trial eligibility recommendations.Journal of Clinical Oncology · 2026
9. Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: A real-world analysis.Journal of Clinical Oncology · 2026
10. PSA nadir–stratified outcomes of ARPI doublet and docetaxel triplet therapy in metastatic prostate cancer.Journal of Clinical Oncology · 2026
11. Artificial intelligence–enabled analysis of unstructured EHR data for identification of actionable HER2-low breast cancer phenotypes.Journal of Clinical Oncology · 2026
12. AI-enabled clinical trial framework for end-to-end site recommendation and enrollment projection.Journal of Clinical Oncology · 2026
13. Real-world effectiveness of MET inhibitors versus immunotherapy ± chemotherapy in 1L for patients with MET exon 14 skipping mutations in non-small cell lung cancer.Journal of Clinical Oncology · 2026
14. Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib.Journal of Clinical Oncology · 2026
15. Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.Journal of Clinical Oncology · 2026
16. Association of mRNA COVID-19 vaccination near immune checkpoint inhibitor initiation with outcomes: A real-world analysis.Journal of Clinical Oncology · 2026
17. Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform: A Nonrandomized Clinical Trial.2026
18. Harmonizing Logical Observation Identifiers Names and Codes (LOINC) Codes and Units in Real-World Oncology Data: Method Development and EvaluationJMIR Medical Informatics · 2026
19. The Music Market in the Age of Streaming: Platform Power, Algorithms, and Artistic Creativity2026
20. Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancerSHILAP Revista de lepidopterología · 2026